Edina Dialysis Of Davita is a medicare approved dialysis facility center in Edina, Minnesota and it has 16 dialysis stations. It is located in Hennepin county at 6565 France Ave S, Edina, MN, 55435. You can reach out to the office of Edina Dialysis Of Davita at (952) 920-8371. This dialysis clinic is managed and/or owned by Davita. Edina Dialysis Of Davita has the following ownership type - Profit. It was first certified by medicare in November, 1990. The medicare id for this facility is 242501 and it accepts patients under medicare ESRD program.
| Name | Edina Dialysis Of Davita |
|---|---|
| Location | 6565 France Ave S, Edina, Minnesota |
| No. of Dialysis Stations | 16 |
| Medicare ID | 242501 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 6565 France Ave S, Edina, Minnesota, 55435 | |
| (952) 920-8371 | |
News Archive
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Dr Kornelia Kotseva, Consultant Cardiologist and the Project Manager for the EUROASPIRE III survey commented "despite the increase in prophylactic drug therapy, the majority of coronary patients in Europe have still not achieved the blood pressure target and two out of five are not achieving the total cholesterol goal".
Deep in the middle of our heads lies a tiny nub of nerve cells that play a key role in how hungry we feel, how much we eat, and how much weight we gain. Around the clock, they produce a "grandfather" form of several hormones that help us regulate these crucial functions.
A drug commonly used to treat leukaemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
› Verified 4 days ago
| NPI Number | 1659335131 |
| Doing Business As | Total Renal Care Inc |
| Address | 6565 France Ave S # 109 Edina, Minnesota, 55435 |
| Phone Number | (952) 925-9339 |
News Archive
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Dr Kornelia Kotseva, Consultant Cardiologist and the Project Manager for the EUROASPIRE III survey commented "despite the increase in prophylactic drug therapy, the majority of coronary patients in Europe have still not achieved the blood pressure target and two out of five are not achieving the total cholesterol goal".
Deep in the middle of our heads lies a tiny nub of nerve cells that play a key role in how hungry we feel, how much we eat, and how much weight we gain. Around the clock, they produce a "grandfather" form of several hormones that help us regulate these crucial functions.
A drug commonly used to treat leukaemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 18 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 22 |
News Archive
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Dr Kornelia Kotseva, Consultant Cardiologist and the Project Manager for the EUROASPIRE III survey commented "despite the increase in prophylactic drug therapy, the majority of coronary patients in Europe have still not achieved the blood pressure target and two out of five are not achieving the total cholesterol goal".
Deep in the middle of our heads lies a tiny nub of nerve cells that play a key role in how hungry we feel, how much we eat, and how much weight we gain. Around the clock, they produce a "grandfather" form of several hormones that help us regulate these crucial functions.
A drug commonly used to treat leukaemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 33 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 265 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Dr Kornelia Kotseva, Consultant Cardiologist and the Project Manager for the EUROASPIRE III survey commented "despite the increase in prophylactic drug therapy, the majority of coronary patients in Europe have still not achieved the blood pressure target and two out of five are not achieving the total cholesterol goal".
Deep in the middle of our heads lies a tiny nub of nerve cells that play a key role in how hungry we feel, how much we eat, and how much weight we gain. Around the clock, they produce a "grandfather" form of several hormones that help us regulate these crucial functions.
A drug commonly used to treat leukaemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Edina Dialysis Of Davita with elevated calcium levels.
| Patients with hypercalcemia | 34 |
| Hypercalcemia patient months | 277 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 40 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 22 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 30 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 25 |
| Patients with Serumphosphor greater than 7 mg/dL | 17 |
News Archive
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Dr Kornelia Kotseva, Consultant Cardiologist and the Project Manager for the EUROASPIRE III survey commented "despite the increase in prophylactic drug therapy, the majority of coronary patients in Europe have still not achieved the blood pressure target and two out of five are not achieving the total cholesterol goal".
Deep in the middle of our heads lies a tiny nub of nerve cells that play a key role in how hungry we feel, how much we eat, and how much weight we gain. Around the clock, they produce a "grandfather" form of several hormones that help us regulate these crucial functions.
A drug commonly used to treat leukaemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 26 |
| Patient months included in arterial venous fistula and catheter summaries | 194 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 88 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 7 |
News Archive
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Dr Kornelia Kotseva, Consultant Cardiologist and the Project Manager for the EUROASPIRE III survey commented "despite the increase in prophylactic drug therapy, the majority of coronary patients in Europe have still not achieved the blood pressure target and two out of five are not achieving the total cholesterol goal".
Deep in the middle of our heads lies a tiny nub of nerve cells that play a key role in how hungry we feel, how much we eat, and how much weight we gain. Around the clock, they produce a "grandfather" form of several hormones that help us regulate these crucial functions.
A drug commonly used to treat leukaemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 32 |
| Hospitalization Rate in facility | 176.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 370.8 |
| Hospitalization Rate: Lower Confidence Limit | 89.1 |
News Archive
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Dr Kornelia Kotseva, Consultant Cardiologist and the Project Manager for the EUROASPIRE III survey commented "despite the increase in prophylactic drug therapy, the majority of coronary patients in Europe have still not achieved the blood pressure target and two out of five are not achieving the total cholesterol goal".
Deep in the middle of our heads lies a tiny nub of nerve cells that play a key role in how hungry we feel, how much we eat, and how much weight we gain. Around the clock, they produce a "grandfather" form of several hormones that help us regulate these crucial functions.
A drug commonly used to treat leukaemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at Edina Dialysis Of Davita were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 16.5 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 31.9 |
| Readmission Rate: Lower Confidence Limit | 6.6 |
News Archive
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Dr Kornelia Kotseva, Consultant Cardiologist and the Project Manager for the EUROASPIRE III survey commented "despite the increase in prophylactic drug therapy, the majority of coronary patients in Europe have still not achieved the blood pressure target and two out of five are not achieving the total cholesterol goal".
Deep in the middle of our heads lies a tiny nub of nerve cells that play a key role in how hungry we feel, how much we eat, and how much weight we gain. Around the clock, they produce a "grandfather" form of several hormones that help us regulate these crucial functions.
A drug commonly used to treat leukaemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Edina Dialysis Of Davita get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.1 (As Expected) |
| SIR: Upper Confidence Limit | 3.62 |
| SIR: Lower Confidence Limit | .18 |
News Archive
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Dr Kornelia Kotseva, Consultant Cardiologist and the Project Manager for the EUROASPIRE III survey commented "despite the increase in prophylactic drug therapy, the majority of coronary patients in Europe have still not achieved the blood pressure target and two out of five are not achieving the total cholesterol goal".
Deep in the middle of our heads lies a tiny nub of nerve cells that play a key role in how hungry we feel, how much we eat, and how much weight we gain. Around the clock, they produce a "grandfather" form of several hormones that help us regulate these crucial functions.
A drug commonly used to treat leukaemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Edina Dialysis Of Davita's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 27 |
| Transfusion Rate in facility | 30.3 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 177 |
| Transfusion Rate: Lower Confidence Limit | 6.4 |
News Archive
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Dr Kornelia Kotseva, Consultant Cardiologist and the Project Manager for the EUROASPIRE III survey commented "despite the increase in prophylactic drug therapy, the majority of coronary patients in Europe have still not achieved the blood pressure target and two out of five are not achieving the total cholesterol goal".
Deep in the middle of our heads lies a tiny nub of nerve cells that play a key role in how hungry we feel, how much we eat, and how much weight we gain. Around the clock, they produce a "grandfather" form of several hormones that help us regulate these crucial functions.
A drug commonly used to treat leukaemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at Edina Dialysis Of Davita lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 171 |
| Mortality Rate in facility | 16.2 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 24.2 |
| Mortality Rate: Lower Confidence Limit | 10.4 |
News Archive
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Dr Kornelia Kotseva, Consultant Cardiologist and the Project Manager for the EUROASPIRE III survey commented "despite the increase in prophylactic drug therapy, the majority of coronary patients in Europe have still not achieved the blood pressure target and two out of five are not achieving the total cholesterol goal".
Deep in the middle of our heads lies a tiny nub of nerve cells that play a key role in how hungry we feel, how much we eat, and how much weight we gain. Around the clock, they produce a "grandfather" form of several hormones that help us regulate these crucial functions.
A drug commonly used to treat leukaemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
› Verified 4 days ago
News Archive
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.
Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.
Dr Kornelia Kotseva, Consultant Cardiologist and the Project Manager for the EUROASPIRE III survey commented "despite the increase in prophylactic drug therapy, the majority of coronary patients in Europe have still not achieved the blood pressure target and two out of five are not achieving the total cholesterol goal".
Deep in the middle of our heads lies a tiny nub of nerve cells that play a key role in how hungry we feel, how much we eat, and how much weight we gain. Around the clock, they produce a "grandfather" form of several hormones that help us regulate these crucial functions.
A drug commonly used to treat leukaemia is showing potential as a treatment that could slow the progression of the muscle-wasting condition, Duchenne muscular dystrophy.
› Verified 4 days ago